Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

BACKGROUND: We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing. METHODS: Seventeen patients with advance...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lee, J-M, Sarosy, G A, Annunziata, C M, Azad, N, Minasian, L, Kotz, H, Squires, J, Houston, N, Kohn, E C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2010
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2822947/
https://ncbi.nlm.nih.gov/pubmed/20051952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605514
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak